Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis

. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2

	Effect vs placebo  Class NWMA		Effect vs placebo  Sensitivity analysis		Rank
Class	Median	95% CrI	Median	95% CrI	Mean	Median	95% CrI	Pr (best)
LABA/ICS	100.80	(55.50 to 140.10)	100.00	(53.77 to 141.50)	1.7	1	(1 to 3)	0.5
LAMA	92.64	(56.23 to 129.60)	94.23	(56.08 to 134.30)	2.0	2	(1 to 3)	0.3
LABA	87.05	(47.28 to 130.50)	86.88	(46.12 to 132.00)	2.3	2	(1 to 3)	0.2
ICS	28.36	(‐11.93 to 65.70)	28.00	(‐13.34 to 66.90)	4.1	4	(4 to 5)	0.0
^aFor effects versus placebo, smaller values indicate larger benefits of the active treatment. Crl = credible interval. FEV₁ = forced expiratory volume in one second. ICS = inhaled corticosteroid. LABA = long‐acting beta₂‐agonist. LABA/ICS = long‐acting beta₂‐agonist/inhaled corticosteroid. LAMA = long‐acting antimuscarinic antagonist. NWMA = network meta‐analysis. Pr = probability.